XOMA Corp(XOMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XOMA XOMA Corp

Market Closed 12-12 16:00:00 EST

25.22

-1.32

-4.97%

盘后25.22

+0.000.00%

19:59 EST

High27.17	Low25.07	Vol134.62K
Open26.82	D1 Closing26.54	Amplitude7.89%
Mkt Cap312.30M	Tradable Cap241.87M	Total Shares12.38M
T/O3.47M	T/O Rate1.40%	Tradable Shares9.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XOMA","market":"US","secType":"STK","nameCN":"XOMA Corp","latestPrice":25.22,"timestamp":1765573200000,"preClose":26.54,"halted":0,"volume":134622,"hourTrading":{"tag":"盘后","latestPrice":25.22,"preClose":25.22,"latestTime":"19:59 EST","volume":162,"amount":4086.75,"timestamp":1765587567625},"delay":0,"floatShares":9590400,"shares":12383103,"eps":0.821624,"marketStatus":"Market Closed","change":-1.32,"latestTime":"12-12 16:00:00 EST","open":26.82,"high":27.165,"low":25.07,"amount":3474285.53562,"amplitude":0.078937,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.821624,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":517896000000,"exchange":"NASDAQ","adjPreClose":26.54,"preHourTrading":{"tag":"盘前","latestPrice":27.29,"preClose":26.54,"latestTime":"09:08 EST","volume":131,"amount":3593.899981,"timestamp":1765548488106},"postHourTrading":{"tag":"盘后","latestPrice":25.22,"preClose":25.22,"latestTime":"19:59 EST","volume":162,"amount":4086.75,"timestamp":1765587567625},"volumeRatio":1.1425014281622172,"impliedVol":1.3364,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/XOMA","defaultTab":"news","newsList":[{"id":"2590543792","title":"Why Is XOMA Royalty Stock Sinking Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590543792","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590543792?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:09","pubTimestamp":1765476540,"startTime":"0","endTime":"0","summary":"XOMA stock plunged after its partner Rezolute Inc. reported disappointing trial results for their product Ersodetug.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49343120/why-is-xoma-royalty-stock-sinking-thursday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49343120/why-is-xoma-royalty-stock-sinking-thursday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU2360032135.SGD","LU2125154935.USD","BK4161","HI","BK4139","RZLT","LU0029874061.USD","LU2125154778.USD","LU0128526141.USD","XOMA"],"gpt_icon":0},{"id":"2590543689","title":"XOMA Royalty Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2590543689","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590543689?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:48","pubTimestamp":1765475280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XOMA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 12:48 ET (17:48 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOMA"],"gpt_icon":0},{"id":"2590115405","title":"XOMA Royalty Corp (Pre-Reincorporation) : Leerink Partners Cuts Target Price to $45 From $58","url":"https://stock-news.laohu8.com/highlight/detail?id=2590115405","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590115405?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:06","pubTimestamp":1765462006,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH11D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XOMA","BK4139"],"gpt_icon":0},{"id":"2590323756","title":"XOMA Royalty Initiated at Buy by LUCID CAPITAL MARKETS","url":"https://stock-news.laohu8.com/highlight/detail?id=2590323756","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590323756?lang=en_us&edition=fundamental","pubTime":"2025-12-10 01:21","pubTimestamp":1765300860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XOMA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 12:21 ET (17:21 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XOMA"],"gpt_icon":0},{"id":"2589381343","title":"XOMA Royalty Completes Acquisition of Mural Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2589381343","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589381343?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:39","pubTimestamp":1764945551,"startTime":"0","endTime":"0","summary":"XOMA Royalty  said Friday it has completed its previously announced acquisition of Mural Oncology .The acquisition was approved by Mural shareholders on Oct. 24 and later was sanctioned by the Irish High Court on Dec. 3, XOMA Royalty said.Mural Oncology shares will be delisted from Nasdaq and deregistered, XOMA Royalty said.Price: 31.13, Change: +0.13, Percent Change: +0.42","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MURA","XOMA","BK4139"],"gpt_icon":0},{"id":"2589381854","title":"BRIEF-Xoma Royalty Announces Closing Of Transaction To Acquire Mural Oncology PLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2589381854","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589381854?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:00","pubTimestamp":1764943235,"startTime":"0","endTime":"0","summary":"BRIEF-Xoma Royalty Announces Closing Of Transaction To Acquire Mural Oncology PLCDec 5 (Reuters) - Xoma Royalty Corp XOMA.O:XOMA ROYALTY ANNOUNCES CLOSING OF TRANSACTION TO ACQUIRE MURAL ONCOLOGY PLCSource text: ID:nGNX5VHzZVFurther company coverage: XOMA.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUAYLFJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XOMA"],"gpt_icon":0},{"id":"2589081884","title":"XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology Plc","url":"https://stock-news.laohu8.com/highlight/detail?id=2589081884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589081884?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:00","pubTimestamp":1764943200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUAYLFJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XOMA"],"gpt_icon":0},{"id":"2586250400","title":"Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586250400?lang=en_us&edition=fundamental","pubTime":"2025-11-26 22:00","pubTimestamp":1764165600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUA9YFMB9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MURA","BK4139","XOMA"],"gpt_icon":0},{"id":"2586250233","title":"Mural Oncology Plc - Total Cash Consideration of $2.035 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586250233?lang=en_us&edition=fundamental","pubTime":"2025-11-26 22:00","pubTimestamp":1764165600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUA9YFMB9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XOMA","MURA"],"gpt_icon":0},{"id":"2585480351","title":"BRIEF-Xoma Royalty Announces Closing Of Transactions To Acquire Lava Therapeutics N.V.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585480351","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585480351?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:51","pubTimestamp":1763729511,"startTime":"0","endTime":"0","summary":"BRIEF-Xoma Royalty Announces Closing Of Transactions To Acquire Lava Therapeutics N.V.Nov 21 (Reuters) - LAVA Therapeutics NV LVTX.O:XOMA ROYALTY ANNOUNCES CLOSING OF TRANSACTIONS TO ACQUIRE LAVA THER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUA4CNKR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOMA","BK4139","BK4539","LVTX"],"gpt_icon":0},{"id":"2585269148","title":"XOMA Royalty Closes Acquisition of LAVA Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2585269148","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585269148?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:45","pubTimestamp":1763729116,"startTime":"0","endTime":"0","summary":"XOMA Royalty Corporation has completed its previously announced acquisition of all outstanding common shares of LAVA Therapeutics N.V. LAVA shareholders received $1.04 in cash per share and a non-transferable contingent value right , which entitles holders to certain future cash payments. These payments include the right to receive 75% of any net proceeds related to LAVA's two partnered assets and from any out-license or sale of unpartnered programs, as well as up to approximately $0.23 per CVR, depending on the final determination of certain potential liabilities. Following the completion of the transaction, XOMA Royalty now owns 100% of LAVA's successor, and public trading of LAVA shares has been suspended with plans to delist from Nasdaq.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL7pmhjP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOMA","BK4588","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","LVTX","BK4139","LU2210149790.SGD","BK4539","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2585148415","title":"XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.v.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585148415","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585148415?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:45","pubTimestamp":1763729100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUA4CNKR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XOMA","LVTX","BK4139","BK4539"],"gpt_icon":0},{"id":"2583022183","title":"UPDATE: XOMA Q3 Adj. EPS $(0.29) Misses $(0.04) Estimate, Adj. EPS Excludes Gains On Acquisitions Of $0.99 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2583022183","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583022183?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:59","pubTimestamp":1762977555,"startTime":"0","endTime":"0","summary":"UPDATE: XOMA Q3 Adj. EPS $(0.29) Misses $(0.04) Estimate, Adj. EPS Excludes Gains On Acquisitions Of $0.99 Per Share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48816485/update-xoma-q3-adj-eps-0-29-misses-0-04-estimate-adj-eps-excludes-gains-on-acquisitions-of-0-99-per","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"UPDATE: XOMA Q3 Adj. EPS $(0.29) Misses $(0.04) Estimate, Adj. EPS Excludes Gains On Acquisitions Of $0.99 Per Share","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOMA"],"gpt_icon":0},{"id":"2583306771","title":"Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), Xoma (XOMA) and Novavax (NVAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583306771","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583306771?lang=en_us&edition=fundamental","pubTime":"2025-11-13 01:10","pubTimestamp":1762967439,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report), Xoma (XOMA – Re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alkermes-alks-xoma-xoma-and-novavax-nvax-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alkermes-alks-xoma-xoma-and-novavax-nvax-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XOMA","BK4139","BK4585","BK4581","NVAX","XLV","BK4547","BK4137","LU0128526141.USD","XBI","LU0029874061.USD","HCSG","LABU","ALKS","BK4568"],"gpt_icon":0},{"id":"2582376679","title":"XOMA Q3 EPS $0.70 May Not Be Comparable To $(0.04) Estimate, Sales $9.351M Miss $11.467M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376679","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376679?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:37","pubTimestamp":1762951043,"startTime":"0","endTime":"0","summary":"XOMA Q3 EPS $0.70 May Not Be Comparable To $(0.04) Estimate, Sales $9.351M Miss $11.467M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48799778/xoma-q3-eps-0-70-may-not-be-comparable-to-0-04-estimate-sales-9-351m-miss-11-467m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOMA"],"gpt_icon":0},{"id":"2582837687","title":"BRIEF-XOMA Q3 EPS USD 0.7","url":"https://stock-news.laohu8.com/highlight/detail?id=2582837687","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582837687?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:30","pubTimestamp":1762950646,"startTime":"0","endTime":"0","summary":"BRIEF-XOMA Q3 EPS USD 0.7\n\n\nNov 12 (Reuters) - XOMA Q3 operating income USD -1.33 million.\n\nQ3 operating expenses USD 10.681 million\nQ3 net income USD 14.1 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX8F18B9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOMA","BK4139"],"gpt_icon":0},{"id":"2582376301","title":"XOMA Royalty reports Q3 revenue of $9.4 million and year-to-date revenue of $38.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582376301","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582376301?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:30","pubTimestamp":1762950640,"startTime":"0","endTime":"0","summary":"XOMA Royalty Corporation reported income and revenue of $9.4 million for the third quarter of 2025 and $38.4 million for the first nine months of 2025, compared to $7.2 million and $19.8 million for the same periods in 2024. Net income for the third quarter and nine months ended September 30, 2025, was $14.1 million and $25.6 million, respectively, compared to net losses of $17.2 million and $9.9 million in the corresponding 2024 periods. The company received $43.9 million in cash from partners in the first nine months of 2025, including $30.3 million in royalty payments related to commercial sales and $13.6 million in milestone payments and fees. Cash and cash equivalents as of September 30, 2025, totaled $130.6 million, including $85.4 million in restricted cash. During the period, XOMA Royalty completed acquisitions of Turnstone Biologics and HilleVax, announced acquisitions of LAVA Therapeutics and Mural Oncology, and acted as structuring agent for XenoTherapeutics' acquisition of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL5JJSXp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPIX","IE00B64PRP62.GBP","LU2210150020.SGD","BK4539","XOMA","HLVX","IE00B3QW5Z07.USD","BK4588","NDAQ","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD","LVTX"],"gpt_icon":0},{"id":"2582366376","title":"XOMA Q3 Operating Expenses USD 10.681 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582366376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582366376?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:30","pubTimestamp":1762950602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX8F18B9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XOMA"],"gpt_icon":0},{"id":"2582237651","title":"Press Release: XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2582237651","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582237651?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:30","pubTimestamp":1762950600,"startTime":"0","endTime":"0","summary":"Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics.Company acquisitions: --Completed XOMA Royalty's acquisitions of Turnstone Biologics and HilleVax; -- announced acquisitions of LAVA Therapeutics and Mural Oncology; -- acted as structuring agent for XenoTherapeutics' acquisition of ESSA Pharma.Key Pipeline advancements: -- Zevra Therapeutics submitted a Marketing Authorization Application  with the European Medicines Agency  seeking marketing approval for arimoclomol as a treatment for Niemann-Pick Type C; -- Rezolute Bio reconfirmed its expectations to announce topline data in December from its Phase 3 ersodetug trial in patients with congenital hyperinsulinism  and announced alignment with FDA on streamlined design for ongoing Phase 3 trial of ersodetug in tumor HI; --Gossamer Bio expects topline results from PROSERA, its Phase 3 trial of seralutunib in pulmonary atri","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","IE00BN0W2T93.GBP","LU0345780521.USD","MAA","LU0345780281.USD","LU0128526141.USD","IE00BN0W2W23.USD","B","BK4232","LU0029874061.USD","HI","LU0498741114.HKD","BK4585","BK4215","LU1721428933.USD","LU0330918003.SGD","LU2125154778.USD","LU2089279066.USD","03160","LU0788108826.HKD","BK4022","BK4567","IE00BN0W2V16.EUR","LU2413666699.HKD","BK4139","LU2092937221.SGD","R","LU0347712357.USD","BK4081","LU0300736492.USD","LU2041044095.USD","LU0075056555.USD","LU2125154935.USD","LU0498741890.SGD","A","LU2413666426.HKD","LU0788109121.HKD","CVR","LU1543694498.USD","LU0300736062.USD","EMA","BK4017","BK4099","BK4555","BK4588","LU1023059493.AUD","TM","LU2229751404.USD","XOMA","LU0368265764.SGD"],"gpt_icon":0},{"id":"2578540601","title":"Press Release: Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty","url":"https://stock-news.laohu8.com/highlight/detail?id=2578540601","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578540601?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:25","pubTimestamp":1761337500,"startTime":"0","endTime":"0","summary":"NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. The Acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions and the sanction of the scheme of arrangement by the High Court of Ireland.As described above, on October 24, 2025, Mural held the Scheme Meeting and EGM in Dublin, Ireland, in each case relating to the Acquisition. Both meetings were held to seek shareholder approval of the Acqui","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XRA","XOMA","MURA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xoma.com","stockEarnings":[{"period":"1week","weight":-0.1568},{"period":"1month","weight":-0.2499},{"period":"3month","weight":-0.326},{"period":"6month","weight":0.0574},{"period":"1year","weight":-0.1002},{"period":"ytd","weight":-0.0403}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.589744,"avgChangeRate":0.056267},{"month":2,"riseRate":0.487179,"avgChangeRate":-0.011749},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.000111},{"month":4,"riseRate":0.487179,"avgChangeRate":-0.011164},{"month":5,"riseRate":0.538462,"avgChangeRate":0.057471},{"month":6,"riseRate":0.435897,"avgChangeRate":0.003996},{"month":7,"riseRate":0.45,"avgChangeRate":-0.005749},{"month":8,"riseRate":0.475,"avgChangeRate":0.052237},{"month":9,"riseRate":0.35,"avgChangeRate":-0.010798},{"month":10,"riseRate":0.4,"avgChangeRate":-0.033618},{"month":11,"riseRate":0.525,"avgChangeRate":0.022745},{"month":12,"riseRate":0.45,"avgChangeRate":0.041932}],"exchange":"NASDAQ","name":"XOMA Corp","nameEN":"XOMA Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"XOMA Corp(XOMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest XOMA Corp(XOMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"XOMA Corp,XOMA,XOMA Corp股票,XOMA Corp股票老虎,XOMA Corp股票老虎国际,XOMA Corp行情,XOMA Corp股票行情,XOMA Corp股价,XOMA Corp股市,XOMA Corp股票价格,XOMA Corp股票交易,XOMA Corp股票购买,XOMA Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"XOMA Corp(XOMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest XOMA Corp(XOMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}